Warrants and Share-based Payment

6 Months Ended

Jun. 30, 2021

Note 7—Warrants and Share-based Payment

Share-based

Payment

Ascendis Pharma A/S has established warrant programs and equity-settled share-based payment transactions, as an incentive for all its employees, members of its Board of Directors and select external consultants.

Warrants are granted by the Company’s Board of Directors in accordance with authorizations given to it by the shareholders of the Company. As of June 30, 2021, 11,023,308 warrants have been granted, of which 19,580 warrants have been cancelled, 4,327,249 warrants have been exercised, 2,168 warrants have expired without being exercised, and 608,488 warrants have been forfeited. As of June 30, 2021, the Company’s Board of Directors was authorized to grant up to 2,603,979 additional warrants to employees, board members and select consultants without preemptive subscription rights for the shareholders of the Company. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK 1. The exercise price is fixed at the fair market value of the Company’s ordinary shares at the time of grant as determined by the Company’s Board of Directors. The exercise prices of outstanding warrants under the Company’s warrant programs range from €6.48 to €145.5 depending on the grant dates. Vested warrants may be exercised in two or four annual exercise periods. Apart from exercise prices and exercise periods, the programs are similar.

Warrant Activity

The following table specifies the warrant activity during the six months ended June 30, 2021:


	Total Warrants			Weighted Average Exercise Price EUR

Outstanding at January 1, 2021		6,148,004			69.97

Granted during the period		158,590			120.15
Exercised during the period		(150,604	)		33.51
Forfeited during the period		(90,167	)		121.80

Outstanding at June 30, 2021		6,065,823			71.04

Vested at June 30, 2021		3,565,573			46.23

Warrant Compensation Costs

Warrant compensation costs are determined with a basis in the grant date fair value of the warrants granted and recognized over the vesting period as research and development costs or as selling, general and administrative expenses. For the three months ended June

, 2021 and 2020, and for the six months ended June 30, 2021 and 2020, warrant compensation costs recognized in the consolidated interim statement of profit or loss was €16,320 thousand and €13,415 thousand, and €39,396 thousand and €28,364 thousand, respectively.